Rates of loss of heterozygosity and mitotic recombination in NF2 schwannomas, sporadic vestibular schwannomas and schwannomatosis schwannomas
- PMID: 20729918
- DOI: 10.1038/onc.2010.363
Rates of loss of heterozygosity and mitotic recombination in NF2 schwannomas, sporadic vestibular schwannomas and schwannomatosis schwannomas
Abstract
Biallelic inactivation of the NF2 gene occurs in the majority of schwannomas. This usually involves a combination of a point mutation or multiexon deletion, in conjunction with either a second point mutation or loss of heterozygosity (LOH). We have performed DNA sequence and dosage analysis of the NF2 gene in a panel of 239 schwannoma tumours: 97 neurofibromatosis type 2 (NF2)-related schwannomas, 104 sporadic vestibular schwannomas (VS) and 38 schwannomatosis-related schwannomas. In total, we identified germline NF2 mutations in 86 out of 97 (89%) NF2 patients and a second mutational event in 77 out of 97 (79%). LOH was by far the most common form of second hit. A combination of microsatellite analysis with either conventional comparative genomic hybridization (CGH) or multiplex ligation-dependent probe amplification (MLPA) identified mitotic recombination (MR) as the cause of LOH in 14 out of 72 (19%) total evaluable tumours. Among sporadic VS, at least one NF2 mutation was identified by sequence analysis or MLPA in 65 out of 98 (66%) tumours. LOH occurred in 54 out of 96 (56%) evaluable tumours, but MR only accounted for 5 out of 77 (6%) tested. LOH was present in 28 out of 34 (82%) schwannomatosis-related schwannomas. In all eight patients who had previously tested positive for a germline SMARCB1 mutation, this involved loss of the whole, or part of the long arm, of chromosome 22. In contrast, 5 out of 22 (23%) tumours from patients with no germline SMARCB1 mutation exhibited MR. High-resolution Affymetrix SNP6 genotyping and copy number (CN) analysis (Affymetrix, Santa Clara, CA, USA) were used to determine the chromosomal breakpoint locations in tumours with MR. A range of unique recombination sites, spanning approximately 11.4 Mb, were identified. This study shows that MR is a mechanism of LOH in NF2 and SMARCB1-negative schwannomatosis-related schwannomas, occurring less frequently in sporadic VS. We found no evidence of MR in SMARCB1-positive schwannomatosis, suggesting that susceptibility to MR varies according to the disease context.
Similar articles
-
The molecular pathogenesis of schwannomatosis, a paradigm for the co-involvement of multiple tumour suppressor genes in tumorigenesis.Hum Genet. 2017 Feb;136(2):129-148. doi: 10.1007/s00439-016-1753-8. Epub 2016 Dec 5. Hum Genet. 2017. PMID: 27921248 Free PMC article. Review.
-
Identification of genetic aberrations on chromosome 22 outside the NF2 locus in schwannomatosis and neurofibromatosis type 2.Hum Mutat. 2005 Dec;26(6):540-9. doi: 10.1002/humu.20255. Hum Mutat. 2005. PMID: 16287142
-
Phenotypic and genotypic overlap between mosaic NF2 and schwannomatosis in patients with multiple non-intradermal schwannomas.Hum Genet. 2018 Jul;137(6-7):543-552. doi: 10.1007/s00439-018-1909-9. Epub 2018 Jul 13. Hum Genet. 2018. PMID: 30006736 Clinical Trial.
-
Segmental neurofibromatosis type 2: discriminating two hit from four hit in a patient presenting multiple schwannomas confined to one limb.BMC Med Genomics. 2015 Jan 24;8:2. doi: 10.1186/s12920-015-0076-2. BMC Med Genomics. 2015. PMID: 25739810 Free PMC article.
-
Neurofibromatosis type 2 and von Hippel-Lindau disease: from gene cloning to function.Glia. 1995 Nov;15(3):297-307. doi: 10.1002/glia.440150310. Glia. 1995. PMID: 8586465 Review.
Cited by
-
Increased growth rate of vestibular schwannoma after resection of contralateral tumor in neurofibromatosis type 2.Neuro Oncol. 2011 Oct;13(10):1125-32. doi: 10.1093/neuonc/nor101. Epub 2011 Jul 28. Neuro Oncol. 2011. PMID: 21798887 Free PMC article.
-
Brigatinib causes tumor shrinkage in both NF2-deficient meningioma and schwannoma through inhibition of multiple tyrosine kinases but not ALK.PLoS One. 2021 Jul 15;16(7):e0252048. doi: 10.1371/journal.pone.0252048. eCollection 2021. PLoS One. 2021. PMID: 34264955 Free PMC article.
-
The molecular pathogenesis of schwannomatosis, a paradigm for the co-involvement of multiple tumour suppressor genes in tumorigenesis.Hum Genet. 2017 Feb;136(2):129-148. doi: 10.1007/s00439-016-1753-8. Epub 2016 Dec 5. Hum Genet. 2017. PMID: 27921248 Free PMC article. Review.
-
Proteomic screening identifies PML/p53 axis as a potential treatment target of facial nerve schwannomas.Am J Transl Res. 2020 Aug 15;12(8):4237-4250. eCollection 2020. Am J Transl Res. 2020. PMID: 32913501 Free PMC article.
-
Mutations affecting BRAF, EGFR, PIK3CA, and KRAS are not associated with sporadic vestibular schwannomas.Virchows Arch. 2013 Feb;462(2):211-7. doi: 10.1007/s00428-012-1342-8. Epub 2012 Dec 8. Virchows Arch. 2013. PMID: 23224067
Publication types
MeSH terms
Supplementary concepts
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous